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Long-term strategies for thyroid health monitoring after 
nuclear accidents: recommendations from an Expert Group 
convened by IARC 
An international multidisciplinary Expert Group 
convened by the International Agency for Research on 
Cancer (IARC) evaluated scientific evidence to formulate 
recommendations about long-term strategies for thyroid 
health monitoring after a nuclear power plant accident. 
The work of the Expert Group was published as IARC 
Technical Publication No. 46.1 The objective of this Expert 
Group was not evaluation of the thyroid examination 
programmes that were implemented after the past 
nuclear accidents, or recommendations related to thyroid 
health monitoring activities currently in progress.
Since the Chernobyl accident in 1986 in Ukraine, the 
guidelines for overall preparedness and response to 
nuclear emergencies have evolved2 and have contributed 
to the implementation of successful countermeasures 
against radiation exposure from nuclear accidents and 
associated potential adverse health effects.3 In view of 
the established association of thyroid cancer risk with 
radiation exposure, particularly during childhood and 
adolescence, appropriate preparedness and response 
regarding thyroid cancer-related issues are crucial. 
However, currently, no specific guidelines are available 
on thyroid cancer screening in populations affected by 
nuclear accidents.
Previous nuclear power plant accidents, at Three Mile 
Island (PA, USA) in 1979, Chernobyl, and Fukushima 
Daiichi (Japan) in 2011, were quite different to each 
other in terms of the quantity of radionuclides 
released, exposure pathways, and average levels 
of radiation exposure to the thyroid, as well as 
interventions administered. After the Fukushima 
Daiichi and Chernobyl accidents, affected children and 
adolescents underwent thyroid examinations, but the 
implemented programmes differed in the size of the 
population and the length of time since the accident. 
Although questions remain about the potential public 
health benefits of thyroid screening programmes, the 
extensive efforts which were made after the respective 
accidents yielded knowledge and lessons learned that 
are invaluable in guiding preparations for any future 
nuclear accidents.
The guiding principle for any health intervention 
is to maximise benefit and minimise harm, and this 
approach should also be applied to thyroid health 
monitoring after nuclear power plant accidents. With 
this concept in mind, the Expert Group developed the 
following two recommendations on thyroid health 
monitoring after possible future nuclear accidents. 
First, the Expert Group recommends against population 
thyroid screening after a nuclear accident, and second, 
it recommends that consideration be given to offering 
a long-term thyroid monitoring programme for 
higher-risk individuals (ie, those exposed in utero or 
during childhood or adolescence to a thyroid dose of 
≥100–500 mGy) after a nuclear accident. 
For the first recommendation, population thyroid 
screening is herein defined as actively recruiting all 
residents of a defined area, irrespective of exposure level, 
to participate in thyroid examinations followed by clinical 
management according to an established protocol. The 
Expert Group recommends against population thyroid 
screening after a nuclear accident, because the harms 
outweigh the benefits at the population level. Although 
cancer screening can be a valuable public health strategy 
for improving population health, the extents of benefits 
and harms vary depending on several factors, including 
types of cancer, target populations, screening modalities 
and frequency, resources, and social values. Because 
thyroid cancer has a large reservoir of subclinical disease 
in the population,4 population thyroid screening identifies 
cancers that would have developed into clinical cases 
as well as those that would not have been diagnosed if 
the screening had not taken place or would not have 
caused symptoms or death during the patient’s lifetime. 
For example, in South Korea,5 the incidence of thyroid 
cancer increased dramatically without substantial change 
in the already low disease-specific mortality as use of 
thyroid ultrasonography examination in clinical practice 
increased. This phenomenon observed in the South Korea 
and other countries raised concerns about overdiagnosis,6 
which often leads to medical interventions with potential 
risks of complications and negative psychosocial effects.
In the context of overdiagnosis and low disease-
specific mortality,7 recommendations have been devel-
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oped by professional organisations to avoid thyroid 
ultrasonography screening in low-risk, asymptomatic 
adult populations.8 The Expert Group agrees with this 
view for populations, of all ages, affected by nuclear 
accidents, because screening the affected asymptomatic 
populations irrespective of risk levels (ie, thyroid radiation 
dose) is also expected to result in the issues related to 
overdiagnosis without clear public health benefits.
For the second recommendation regarding a long-
term monitoring programme, thyroid monitoring 
programme is herein defined as including education to 
improve health literacy, registration of participants, and 
centralised data collection from thyroid examinations 
and clinical management. Thyroid monitoring is an 
elective activity offered to higher-risk individuals, who 
might choose how and whether to undergo thyroid 
examinations in an effort to benefit from early detection 
and treatment of less advanced disease. Although the 
aim in both screening and monitoring programmes is 
early detection of cancer in asymptomatic individuals, 
the public health approach and objectives are different. 
In a thyroid monitoring programme, the starting point 
is the individual instead of the population; higher-risk 
individuals are offered the programme rather than 
actively recruited to the programme, and they are 
empowered to make an informed decision consistent 
with their values, preferences, and context.
Although some data have shown clinical usefulness 
of screening for differentiated thyroid cancer in high-
risk populations (eg, for familial non-medullary thyroid 
cancer),9 the evidence for benefits of early diagnosis is 
currently scarce in children.10 In view of the risks related 
to overdiagnosis, the potential consequences of thyroid 
examinations should be discussed between the affected 
families and clinicians within the WHO Framework on 
integrated people-centred health services. Well informed 
individuals who perceive that potential benefits outweigh 
potential harms for themselves should receive high-
quality services from qualified medical professionals in an 
organised monitoring programme, with governmental 
authority oversight and quality assurance within an 
achievable and sustainable financing strategy.
Higher-risk individuals who might benefit from a 
thyroid monitoring programme after a nuclear accident 
are defined herein by the Expert Group as those exposed 
in utero or during childhood or adolescence with a 
thyroid dose of 100–500 mGy or more. This range of 
100–500 mGy was proposed by the Expert Group as 
a practical definition of an actionable level to offer 
inclusion into the thyroid monitoring programme. This 
actionable level should not be confused with radiation 
protection limits. The choice of a thyroid dose range 
reflects the option to be more inclusive (lower actionable 
levels) or to be more efficient (higher actionable levels) 
in monitoring and identifying radiation-associated 
thyroid disease in individuals at elevated risk. The Expert 
Group acknowledges that further research is necessary 
and the optimal actionable level might need to be 
revised as new evidence emerges.
Notably, the recommendation of establishing a 
thyroid dose actionable level does not mean that 
nothing should be offered to an individual below this 
exposure level. Despite the potential harms, some 
low-risk individuals with fears about thyroid cancer 
might opt to undergo thyroid examinations to seek 
reassurance. Low-risk individuals who are willing to 
have a thyroid examination after receiving a detailed 
explanation of potential benefits and harms should be 
offered a thyroid examination within the framework of 
the organised thyroid monitoring programme.
Any thyroid monitoring programme for higher-risk 
individuals should be initiated as soon as it is practically 
feasible and should extend through adulthood, given 
the evidence that thyroid cancer risk from radiation 
exposure during childhood or adolescence continues 
into adult life. Intervals between individual thyroid 
examinations might range between 2 years and 5 years 
and can be adjusted on the basis of clinical findings and 
screening modalities. Benefits and harms of thyroid 
examinations should be balanced against the presence 
of comorbidities, and a decision to stop should be an 
informed individual choice. 
The recommendations were developed in the context 
of considerations relevant to exposure to any toxic 
(including radioactive) substances, and preparedness and 
response to nuclear accidents, given their implications 
for decision making about thyroid health monitoring. 
The considerations include the establishment of a health 
surveillance programme, including cancer registration, as 
well as a dynamic risk communication programme, in the 
vicinity of nuclear installations before a nuclear accident, 
and also implementing timely and appropriate active 
dosimetry monitoring and protective actions, such as an 
iodine thyroid blocking programme, immediately after a 
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nuclear accident.
The Expert Group acknowledges that there might be 
important considerations in addition to the scientific 
evidence during such decision making processes, 
including socioeconomic implications, health-care 
resources, and social values, and that the final decisions 
are made by the government, the relevant authorities, 
and the society affected by the nuclear accident. These 
recommendations are intended to serve as a reference 
primarily for government officials, policy makers, and 
health professionals who would be involved in the 
decision making, planning, and implementation of 
thyroid monitoring in case of a nuclear accident.
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